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Abstract
Objectives: 18F-choline is a useful tracer for detecting tumours with high lipogenesis.
Knowledge of its biodistribution pattern is essential to recognise physiological variants. The
aim of this study was to describe the physiologic distribution of 18F-choline and pitfalls in patients
with breast cancer.
Methods: Twenty-one consecutive patients with breast cancer (10 premenopausal and 11 post-
menopausal women; mean age, 52.82 10.71 years) underwent 18F-choline positron emission
tomography (PET)/computed tomography (CT) for staging. Whole-body PET/CT was acquired
after 40 minutes of 18F-choline uptake. Acquired PET images were measured semiquantitatively.
Results: All patients showed pitfalls unrelated to breast cancer. These findings were predomi-
nantly caused by physiological glandular uptake in the liver, spleen, pancreas, bowels, axial
skeleton (85%-100%), inflammation and benign changes (4.76%), appendicular skeleton (4.76%–
19.049%), and site contamination (61.9%). In <1%, a concomitant metastatic neoplasm was found.
The breast showed higher physiological uptake in premenopausal compared with postmenopausal
woman (18F-choline maximum standardised uptake values [g/dL] of the right breast¼ 2.04
 0.404 vs 1.59 0.97 and left breast¼ 2.00 0.56 vs 1.93 1.28, respectively).
Conclusion: 18F-choline uptake was higher in premenopausal women. Physiological 18F-choline
uptake was observed in many sites, representing possible pathologies.
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Introduction
Fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) is extensively used
as an imaging biomarker for diagnosing
and monitoring treatment responses of
patients with cancer. Recently, newer imag-
ing biomarkers such as fluorine 18 (18F)-
choline1–3 and carbon 11 (11C)-choline2
have been evaluated for their greater specif-
icity to assess proliferation and choline
metabolism, respectively. The utility of
18F-choline in breast cancer has not been
widely studied.4–6 For example, Aboagye
and Bhujwalla7 showed a unique phenotype
of increased choline metabolism in the
transition of normal human mammary
epithelial cells to immortalised, oncogene-
transformed, and finally non-metastatic
and metastatic cancer. In their study,
the phosphocholine levels incrementally
increased with progression such that
breast cancer cells had the highest phospho-
choline levels. Further studies in mammary
epithelial cells found that the aberrant
increases in phosphocholine metabolite
levels are caused by the expression of the
biosynthetic enzyme choline kinase-a7.
Coincidentally, choline kinase activity and
cellular phosphocholine levels are regulated
by the growth factor receptor–mitogen-
activated protein kinase pathway in
mammalian cells—the same pathway that
modulates oestrogen-independent growth.8
Considering the pharmacological features
and properties of choline, the uptake of
the tracer can occur in physiological or
benign conditions such as cell membrane
synthesis as well as in malignancies.3
Thus, the aim of the present study was to
describe and discuss the pattern of physio-
logical sites of 18F-choline uptake, common
pitfalls, and variations in 18F-choline
uptake in women.
Materials and methods
We conducted a prospective study of
patients who were recruited based on mam-
mographic criteria of having Breast
Imaging Reporting and Data System class
4 or 5 for suspicious breast cancer. Patients
with recurrent disease did not undergo
treatment before positron emission tomog-
raphy/computed tomography (PET/CT).
All patients received an intravenous
injection of 3 mCi of 18F-choline and were
subsequently rested for a mean of approxi-
mately 30–45 minutes before undergoing
PET/CT. Image acquisition was performed
using an integrated PET/CT device
(Siemens Biograph-64; Siemens Health
Care, Erlangen Germany) comprising a
3D-PET camera (lutetium oxyorthosilicate)
and a 64-multi-detector CT scanner.
Patients were allowed to take normal, shal-
low breaths during acquisition of the PET/
CT. CT without contrast was performed
first at 120 kV, 150 mAs transmission with
a pitch of 0.8 (5.0-mm slice thickness) from
the base of the skull to the proximal thighs
for anatomical localisation and attenuation
correction to rescale the FDG/PET image
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attenuation without delay at the second
time point.
PET was performed contemporaneously
with acquisition for 3 minutes per bed posi-
tion. CT data were resized from a 512 512
matrix to a 128 128 matrix to match the
PET data and allow image superposition
followed by generation of CT transmission
maps. PET image datasets were iteratively
reconstructed using the ordered-subsets
expectation maximisation algorithm with
segmented measured attenuation correction
(two iterations, 28 subsets) of the CT data.
Coregistered images were displayed on a
Siemens-Leonardo Workstation (Siemens
Health Care). 18F-choline FDG PET/CT
was performed 1 week following a success-
ful 18F-choline PET/CT study. SUVmax
values served as a surrogate marker. The
significance of the difference between
SUVmax values of the pre- and postmeno-
pausal women was evaluated using
the Student t test, and p0.05 indi-
cates significance.
The ethics review boards of the
University Putra, Malaysia and the
Hospital of the University of Kebangsaan,
Malaysia approved this study. All patients
recruited into this study were granted writ-
ten and verbal consent.
Results
Twenty-one consecutive patients underwent
18F-choline PET/CT imaging for presurgi-
cal staging of breast cancer (Table 1).
Patients were 11 premenopausal and 10
postmenopausal women. The mean age of
the patients was 54.48 12.17 years. The
majority of the patients showed biopsy-
proven malignant breast tumours;
18 patients had invasive ductal carcinoma,
and 3 patients had benign tumours. All
patients with invasive ductal carcinoma
showed increased 18F-choline uptake (max-
imum standardised uptake value
[SUVmax]¼ 1.66 0.26 g/dL), Figures 1–2.
We observed physiological 18F-choline
uptake in the liver, pancreas, spleen, sali-
vary and lacrimal glands, and owing to
renal excretion, in the urinary tract. Other
sites of less intense tracer uptake were the
bone marrow and intestines (Figure 3).
Table 1. Patients’ characteristics
Patients (N¼ 21)




Choroid Plexus 18 (85.7)
Pituitary Gland 19 (90.4)
Lacrimal gland 8 (38.0)
Falx cerebri 1 (4.76)
Neck
Salivary Gland 21 (100)
Submandibular Gland 21 (100)
Parotid Glands 20 (95.2)
Tonsils 6 (28.5)
















Axial spine 21 (100)
Peripheral skeleton
Pubic bone 4 (19.04)
Muscles
Biceps 3 (14.28)
Latissumus dorsi 4 (19.04)
Pectoralis major 1 (4.76)
Second pathology
Lung Metastasis 1 (4.76)
Axillary lymph node 1 (4.76)
Degenerative bone disease 3 (14.28)
Artefact
Injection site contamination 13 (61.9)
All data are presented as number (percentage) of patients,
unless otherwise indicated.
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The background 18F-choline uptake in pre-
menopausal women was significantly higher
than that in postmenopausal women
(Table 2).
Brain
In the brain, choline uptake in the normal
cerebral cortex and basal ganglia is less
intense compared with FDG.6 In the pre-
sent study, however, certain areas of the
brain showed moderate to intense uptake
in the falx cerebri (4.76%), choroid plexus
(85.7%), and lacrimal gland (38.0%)
(Figure 4). The pituitary gland showed the
highest 18F-choline uptake in the brains of
this group of subjects (Figure 4b).
Figure 2. Axial-fused choline PET/CT detected
avid choline (maximum standardized uptake
volume, 13.3) uptake in the primary breast cancer
lesion (circle).
Figure 3. Maximum intensity projection (MIP)
positron emission tomography (PET) 18F-choline
images show physiological 18F-choline uptake in
liver, pancreas, spleen, salivary and lacrimal glands
and, owing to renal excretion, in the urinary tract.
Other sites of less intense tracer uptake were bone
marrow and intestines.
Figure 1. Maximum intensity projection
(MIP)-positron emission tomography (PET)
detected physiological 18F-choline uptake in
the reticuloendothelial system and in the
salivary glands.
Table 2. Mean 18F-choline uptake in both breasts







Right Breast 2.04 0.404 1.59 0.97 <0.05
Left Breast 2.00 0.56 1.93 1.28 <0.05
p<0.05, statistically significant (Student t test). SUVmax,
maximum standardised uptake value.
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Neck
Normal lymphatic tissue may display low to
moderate choline uptake in the head and
neck, particularly in the salivary glands, lin-
gual and palatine tonsils, and at the base of
the tongue because of the physiological
activity associated with the lymphatic
tissue in Waldeyer’s ring.2 In the present
study, we observed symmetrical 18F-choline
uptake in the submandibular gland (100%)
(Figure 5) and in the parotid gland (100%)
(Figure 6). Diffuse symmetric uptake can
be seen in the normal thyroid gland (see
Figure 7). Diffuse thyroid uptake can
occur in association with inflammatory
changes such a thyroiditis or Graves’ dis-
ease.4 Focal thyroid uptake occurs in
benign thyroid nodules or malignancies,
and further work-up is warranted in such
Figure 5. 18F-choline positron emission tomography (PET) image (coronal and axial views) with increased
18F-choline activity at the base of tongue muscle (hair-line) and in the submandibular glands (circle).
Figure 4. 18F-choline positron emission tomography (PET) image (axial view) in a patient who had
undergone 18F-choline PET/CT. (a) Increased activity is similar to that of the falx cerebri. (b, c, d) Uptake at
the pituitary fossa (b). Increased activity in the choroid plexus (c) and lacrimal gland (d).
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cases. Routinely, patients with focal uptake
should be further evaluated due because of
the higher risk that their findings are asso-
ciated with a malignancy. 18F-choline was
incorporated into the mylohyoid muscle
(4.76%) and into the thyroid bed of one
patient (4.76%) (Figure 4).
Abdomen/pelvis
Avid 18F-choline uptake was detected in the
liver, spleen, pancreas, and bowels of all
patients. Good 18F-choline uptake and
excretion were detected in the kidneys and
bladder, respectively (Figure 8). Only one
(4.76%) site with 18F-choline was noted in
the ovaries and uterus of two patients
(9.52%) (Figure 8). Detection of lymph
node metastases may be hampered by high
levels of physiological choline uptake in the
gastrointestinal tract, commonly seen on
18F-choline PET/CT. Fasting is frequently
proposed before patients undergo 18F-cho-
line PET/CT.9
Soft tissue, skeleton, and marrow
After recognising normal choline uptake,
there is relatively low choline uptake in
soft tissues, but conditions of muscular
imbalance, e.g. postsurgery or scoliosis,
may result in increased FDG uptake in
affected muscles.2 In the present study, we
detected 18F-choline uptake in the muscles
(biceps, latissimus dorsi, and pectoralis
major) was the lowest among the other
organ systems (Figure 9). In all patients,
18F-choline uptake in the axial skeleton
was recorded as avid, with scattered
uptake involving the ribs and clavicle,
accounting for <0.05% (Figure 10).
Nevertheless, 18F-choline uptake in the ster-
num was relatively high (30%) (Figure 10).
One site of uptake documented in the rib
was likely attributable to an existing frac-
ture (Figure 11). Pubic bone uptake
(19.04%) was likely related to post-
chemotherapy or radiotherapy effects.
Miscellaneous
Some benign conditions showed a moderate
to intense uptake of choline, which included
Figure 6. 18F-choline positron emission tomog-
raphy (PET) image (coronal view) with 18F-choline
avid parotids and submandibular gland.
Figure 7. 18F-choline positron emission
tomography (PET) image (sagittal view) in a
patient with 18F-choline avid thyroid gland in
favour of thyroiditis (circle).
Saad et al. 3143
healing of the surgical incision sites, sites of
previous radiation therapy (no or low
uptake), joint prosthesis (not infected),
degenerative joint disease, and stomal sites,
(Figure 10). Further, we documented 18F-
choline contamination at the injection site
in 61.9% of the patients (Figure 12) and an
18F-choline avid flow artefact due to a bolus
of venous flow (Figure 13). We also detected
18F-choline uptake in lung metastasis
(4.76%) and axillary lymph nodes (4.76%).
Discussion
Choline metabolism is elevated in the
majority of tumours, and accounts for
increased phospholipid synthesis required
for cell membrane turnover.8 In mammary
epithelial cells, increased intracellular phos-
phocholine levels are associated with malig-
nancy, increasing with malignant
transformation and progression.7 Thus, ele-
vated choline levels in breast cancer are well
documented. For the 21 patients in the pre-
sent study, median choline uptake values
were 10-fold lower in normal breast and
lung tissues compared with those of
tumours and were higher in more aggressive
malignant lesions. These findings are con-
sistent with the in vitro findings of
Aboagye and Bhujwalla,7 who showed ele-
vated phosphocholine levels associated with
malignant transformation and progression
in patients with an underlying malig-
nant tumour.
Figure 8. 18F-choline positron emission tomography (PET) Image (axial and coronal views) in a patient who
had undergone 18F-choline PET/CT. Increased activity is seen liver, spleen, pancreas, gastrointestinal tract,
genital system , urinary bladder and bone marrow.
Figure 9. 18F-choline positron emission
tomography (PET) image (coronal view) showing
symmetrical 18F-choline uptake in the biceps
muscle (circle).
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A range of avid choline uptake values
were observed in the cerebral cortex, falx
cerebri, choroid plexus, pituitary and lacri-
mal glands, whereas choline was conspicu-
ous in the salivary glands, and to some
extent, in tonsillar glands. 18F-choline is
also feasible as a tracer for imaging brain
tumours.10,11 The distribution rate of cho-
line is low in normal white and grey matter
and in other regions of the brain, with the
exceptions of the choroid plexus and the
pituitary gland.12
The physiological choline uptake pat-
terns in female organs are different from
those in male organs. One particularly
notable attribute is elevated choline
kinase-a expression, which promotes cell
division and is regulated by the growth
factor receptor–mitogen-activated protein
kinase pathway.13 Compared with choline
Figure 10. Maximum intensity projection (MIP) positron emission tomography (PET) image (sagittal,
coronal views) showing prevalence of 18F-choline uptake in the axial skeleton, pubic bone and in the
sternum. The increased 18F-choline uptake in the hip joints indicate degenerative changes.
Figure 11. Axial-fused 18F-choline positron emission tomography (PET)/ computed tomography (CT)
images showing (left) increased 18F-choline uptake at an old rib fracture, (right) exhibiting callous union.
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uptake in men, the prevalence of thyroid
inflammatory disease in women is more fre-
quently encountered as an incidental find-
ing on 18F-choline PET/CT.8
Here we detected significant differences
in the values of 18F-choline SUVmax of the
breasts between premenopausal and post-
menopausal women. This was substantiated
by findings that the efficiency of endoge-
nous choline uptake is greater among
premenopausal women because of the up-
regulation of oestrogen production.14–16
The possibility of 18F-choline uptake
into benign tumours may be explained by
an overall increased rate of cell prolifera-
tion, which requires a high rate of synthesis
of cell membranes, which may influence the
uptake of the tracer.10 These differences in
18F-choline uptake were observed in the
three benign breast lesions analysed here.
Further, we detected sites of abnormal
uptake of 18F-choline in inflammatory
sites in 16%17 of patients, which suggests
that certain inflammatory processes show
a relatively high uptake of 18F-choline.
The uptake of 18F-choline associated with
inflammatory conditions may be explained
by the proliferation of certain cells involved
in the genesis of phlogosis, such as
white cells.13
In the abdomen and pelvis, 18F-choline
uptake detected in the liver, spleen, and
pancreas was comparable with that
detected in men. Nonetheless, uptake by
gonadal glands was more frequently
observed in women (ovaries, uterus) com-
pared with in men (testis). High uptake of
11C-choline is normally observed in the liver
and kidney (cortex), where choline is con-
verted into betaine as well as in the pancre-
as and duodenum because of the secretion
of phospholipid-rich pancreatic juice.18
In the spine, 18F-choline avidity was
detected in men and women, although to a
greater extent, and its uptake by the ster-
num and manubrium sterni is more fre-
quently detected following chemotherapy
or radiotherapy. Choline may serve as a
predictive marker for chemotherapy-
responsive patients with prostate cancer
who express high levels of choline kinase.
This hypothesis is based on findings that
the cell-free androgen receptor expression
and choline uptake occurs among those
treated with abiraterone and enzaluta-
mide.19 Thus, choline is a theranostic bio-
marker for women with breast cancer and is
influenced by hormonal expression (proges-
terone or oestrogen). The possibility that
choline serves a surrogate marker for
hormone-dependent breast cancer that pre-
dicts tumour aggressiveness will be
addressed by future research, because total
reliance on determining the immunohisto-
chemical subtypes of breast cancer lineages
hampers treatment efficacy. This hypothesis
Figure 12. Maximum intensity projection (MIP)
PET image. Contamination at the injection site
occurs during 18F-choline injection (arrow).
Figure 13. Maximum intensity projection (MIP)
PET image: 18F-choline intravenous flow artefact
due to bolus of venous flow.
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is supported by the role of choline as a pre-
dictive marker, because it reflects the early
response to abiraterone, detected using
PET/CT, among patients with metastatic
castration-resistant prostate cancer.20
Other incidental findings such as rib frac-
tures were present in these patients.
Liu et al reported increased uptake of
18F-choline in some granulomatous diseases
such as sarcoidosis and tuberculosis.17 In
the present study, one patient with
choline-negative postradiation pneumonitis
was unique, because most inflammatory
conditions should accumulate choline.
Conclusion
18F-choline PET/CT is useful for differenti-
ating the levels of tumour aggressiveness
associated with a tumour’s biochemistry,
physical and chemical properties, as well
as its metabolism. These properties of cho-
line are unique, specifically reflecting
tumour phenotypes. These unique proper-
ties distinguish choline from FDG, because
choline will localise to any part of the body
with high physiological activity. Detailed
knowledge of the technique and interpreta-
tion of 18F-choline PET/CT studies are
required for data interpretation. Not know-
ing these potential causes of misinterpreta-
tion can lead to inaccurate interpretation of
PET images or false-positive results.
Therefore, the new knowledge presented
here of the distribution pattern of 18F-cho-
line in women may subsequently decrease
the number of unnecessary follow-up stud-
ies or procedures that improve patient man-
agement plans and monitoring.
In conclusion, we show here that the
uptake of 18F-choline was higher in preme-
nopausal subjects, and the physiological
uptake of 18F-choline was detected in
many sites of the body, which may mas-
querade as cancers. Our knowledge of the
biodistribution of 18F-choline in female
patients with breast cancers is limited. It is
therefore essential to recognize physiologic
variations to avert false-positive results.
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